• RCCSE中国核心学术期刊（A+）
  • 中国百强报刊
  • 百种中国杰出学术期刊
  • 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国自然科学类核心期刊
  • 中国科技论文统计源期刊
  • 中华医学会优秀期刊
  • 中国精品科技期刊顶尖学术论文（5000）项目来源期刊
  • 入选中国高质量科技期刊分级目录（消化病学）T1级
  • 入选《中国学术期刊影响因子年报（自然科学与工程技术）》Q1区
  • 入选《科技期刊世界影响力指数（WJCI）报告（2022）》
  • RCCSE中国核心学术期刊（A+）
  • 中国百强报刊
  • 百种中国杰出学术期刊
  • 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国自然科学类核心期刊
  • 中国科技论文统计源期刊
  • 中华医学会优秀期刊
  • 中国精品科技期刊顶尖学术论文（5000）项目来源期刊
  • 入选中国高质量科技期刊分级目录（消化病学）T1级
  • 入选《中国学术期刊影响因子年报（自然科学与工程技术）》Q1区
  • 入选《科技期刊世界影响力指数（WJCI）报告（2022）》
Wu Guangbin, Xu Xiaolei, He Miaolong, et al. Application progress of yttrium-90 selective internal radiation therapy in colorectal liver metastases[J]. Chinese Journal of Digestive Surgery, 2025, 24(2): 266-270. DOI: 10.3760/cma.j.cn115610-20241201-00532
Citation: Wu Guangbin, Xu Xiaolei, He Miaolong, et al. Application progress of yttrium-90 selective internal radiation therapy in colorectal liver metastases[J]. Chinese Journal of Digestive Surgery, 2025, 24(2): 266-270. DOI: 10.3760/cma.j.cn115610-20241201-00532
shu

Application progress of yttrium-90 selective internal radiation therapy in colorectal liver metastases

  • 1.

    Clinical Medical School, Qinghai University, Xining 810001, China

  • 2.

    Department of Hepatopancreatobiliary Surgery, Qinghai Research Key Laboratory for Echinococcosis, Qinghai University Affiliated Hospital, Xining 810001, China

  • 3.

    Department of Hepatopancreatobiliary Surgery, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China

  • 4.

    Department of Hepatopancreatobiliary Surgery, Yttrium-90 Precision Interventional Radiotherapy Center for Liver Cancer, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China

Funds: 

Kunlun Talents-Young and Middle-aged Talents Promotion Project in Qinghai Province 2022QHSKXRCTJ17

Young and Middle-aged Fund of Qinghai University Affiliated Hospital ASRF-2021-YB-17

Precision Medicine Research Project of Tsinghua University 2022ZLA005

More Information
  • Corresponding author:

    Feng Xiaobin, Email: 1249486411@qq.com

  • Received Date: November 30, 2024
    Graphical Abstract
    • Abstract

  • In recent years, the incidence of liver metastasis from colorectal cancer has continued to rise, posing a significant threat to human health and life.Although traditional treatments such as surgery and chemotherapy have shown some efficacy in certain patients, options remain limited for those who are not surgical candidates or are resistant to chemotherapy.Yttrium-90 microsphere selective internal radiation therapy, as an innovative local treatment, has fully demonstrated its effectiveness and safety in treating colorectal cancer liver metastasis patients. The authors review the research background, mechanisms, and principles of yttrium-90 microsphere selective internal radiation therapy in the field of colorectal cancer liver metastasis, and to explore its application progress in clinical practice, aiming to provide clinical doctors with more comprehensive and detailed reference information, with the goal of improving treatment outcomes and quality of life for colorectal cancer liver metastasis patients.

    • FullText(HTML)
    • References (36)
  • [1]
    Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
    [2]
    郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
    [3]
    中国医师协会外科医师分会, 中华医学会外科学分会胃肠外科学组, 中华医学会外科学分会结直肠外科学组, 等. 中国结直肠癌肝转移诊断和综合治疗指南(2023版)[J/OL]. 消化肿瘤杂志(电子版), 2023, 15(2): 86-99[2024-11-30]. https://www.jdocn.com/onlinebrowsing/detail_466.html. DOI: 10.19538/j.cjps.issn1005-2208.2023.01.03.
    [4]
    Khatri VP, Chee KG, Petrelli NJ. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies[J]. Surg Oncol, 2007, 16(1): 71-83. DOI: 10.1016/j.suronc.2007.05.001.
    [5]
    Matias M, Casa-Nova M, Faria M, et al. Prognostic factors after liver resection for colorectal liver metastasis[J]. Acta Med Port, 2015, 28(3): 357-369. DOI: 10.20344/amp.4816.
    [6]
    Feng QY, Wei Y, Chen JW, et al. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases[J]. World J Gastroenterol, 2014, 20(15): 4263-4275. DOI: 10.3748/wjg.v20.i15.4263.
    [7]
    Sotelo MJ, García-Paredes B, Aguado C, et al. Role of cetuximab in first-line treatment of metastatic colorectal cancer[J]. World J Gastroenterol, 2014, 20(15): 4208-4219. DOI: 10.3748/wjg.v20.i15.4208.
    [8]
    Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results[J]. J Vasc Interv Radiol, 2005, 16(7): 937-945. DOI: 10.1097/01.RVI.0000161142.12822.66.
    [9]
    Clark ME. Smith RR. Liver-directed therapies in metastatic color-ectal cancer[J]. J Gastrointest Oncol, 2014, 5(5): 374-387. DOI: 10.3978/i.issn.2078-6891.2014.064.
    [10]
    Gulec SA, Pennington K, Wheeler J, et al. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase Ⅱ trial[J]. Am J Clin Oncol, 2013, 36(5): 455-460. DOI: 10.1097/COC.0b013e3182546c50.
    [11]
    中国医师协会介入医师分会临床诊疗指南专委会, 中国研究型医院学会肝胆胰外科专业委员会. 钇-90微球选择性内放射治疗肝脏恶性肿瘤规范化操作专家共识(2024版)[J]. 中华消化外科杂志, 2024, 23(2): 165-178. DOI: 10.3760/cma.j.cn115610-20231025-23164.
    [12]
    Saxena A, Bester L, Shan L, et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases[J]. J Cancer Res Clin Oncol, 2014, 140(4): 537-547. DOI: 10.1007/s00432-013-1564-4.
    [13]
    Gruber-Rouh T, Naguib NN, Eichler K, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period[J]. Int J Cancer, 2014, 134(5): 1225-1231. DOI: 10.1002/ijc.28443.
    [14]
    Yun D, Kim S, Song I, et al. Comparative analysis of laparoscopic versus open surgical radiofrequency ablation for malignant liver tumors[J]. Korean J Hepatobiliary Pancreat Surg, 2014, 18(4): 122-128. DOI: 10.14701/kjhbps.2014.18.4.122.
    [15]
    Veltri A, Guarnieri T, Gazzera C, et al. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival[J]. Radiol Med, 2012, 117(7): 1139-1151. DOI: 10.1007/s11547-012-0803-3.
    [16]
    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2024年版)[J]. 中华消化外科杂志, 2022, 23(4): 429-478. DOI: 10.3760/cma.j.cn115610-20240415-00203.
    [17]
    Gulec SA, Fong Y. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases[J]. Arch Surg, 2007, 142(7): 675-682. DOI: 10.1001/archsurg.142.7.675.
    [18]
    黄鹏, 王万胜, 张磊, 等. 经动脉放射栓塞治疗肝细胞癌的研究进展[J]. 中华放射学杂志, 2021, 55(7): 773-777. DOI: 10.3760/cma.j.cn112149-20200702-00880.
    [19]
    牛娜. 90Y微球选择性内放射治疗在肝细胞癌中的应用及研究进展[J]. 中国癌症杂志, 2021, 31(5): 428-434. DOI: 10.19401/j.cnki.1007-3639.2021.05.009.
    [20]
    Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update[J]. Cancers (Basel), 2020, 12(4): 791. DOI: 10.3390/cancers12040791.
    [21]
    Westcott MA, Coldwell DM, Liu DM, et al. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres[J]. Adv Radiat Oncol, 2016, 1(4): 351-364. DOI: 10.1016/j.adro.2016.08.003.
    [22]
    Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds[J]. Eur J Nucl Med Mol Imaging, 2022, 49(5): 1682-1699. DOI: 10.1007/s00259-021-05600-z.
    [23]
    Benson AB, Venook AP, Adam M, et al. Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(2D): e240029[pⅱ]. DOI: 10.6004/jnccn.2024.0029.
    [24]
    Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies[J]. Radiographics, 2008, 28(1): 101-117. DOI: 10.1148/rg.281075115.
    [25]
    Hermann AL, Dieudonné A, Ronot M, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study[J]. Radiology, 2020, 296(3): 673-684. DOI: 10.1148/radiol.2020191606.
    [26]
    汤钰宏, 范松松, 曹俊, 等. 《原发性肝癌诊疗指南(2024年版)》更新要点[J]. 肝胆胰外科杂志, 2024, 36(10): 583-588. DOI: 10.11952/j.issn.1007-1954.2024.10.002.
    [27]
    Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-64. DOI: 10.1053/j.gastro.2009.09.006.
    [28]
    中国临床肿瘤学会核医学专家委员会, 北京市核医学质量控制和改进中心. 钇-90(90Y)微球选择性内放射治疗原发性和转移性肝癌的中国专家共识[J]. 中华肝脏病杂志, 2021, 29(7): 648-658. DOI: 10.3760/cma.j.cn501113-20210302-00103..
    [29]
    Wang DS, Louie JD, Sze DY. Evidence-based integration of yttrium-90 radioembolization in the contemporary management of hepatic metastases from colorectal cancer[J]. Tech Vasc Interv Radiol, 2019, 22(2): 74-80. DOI: 10.1053/j.tvir.2019.02.007.
    [30]
    Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials[J]. Lancet Oncol, 2017, 18(9): 1159-1171. DOI: 10.1016/S1470-2045(17)30457-6.
    [31]
    Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase Ⅲ trial[J]. J Clin Oncol, 2021, 39(35): 3897-3907. DOI: 10.1200/JCO.21.01839.
    [32]
    Gibbs P, Heinemann V, Sharma NK, et al. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies[J]. Clin Colorectal Cancer, 2018, 17(4): e617-e629. DOI: 10.1016/j.clcc.2018.06.001.
    [33]
    Hendlisz A, Van den Eynde M, Peeters M, et al. Phase Ⅲ trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy[J]. J Clin Oncol, 2010, 28(23): 3687-3694. DOI: 10.1200/JCO.2010.28.5643.
    [34]
    Helmberger T, Golfieri R, Pech M, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-Spheres therapy (CIRT)[J]. Cardiovasc Intervent Radiol, 2021, 44(1): 21-35. DOI: 10.1007/s00270-020-02642-y.
    [35]
    Schaefer N, Grözinger G, Pech M, et al. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT[J]. Clin Colorectal Cancer, 2022, 21(4): 285-296. DOI: 10.1016/j.clcc.2022.09.002.
    [36]
    Azeredo-da-Silva A, de Jesus V, Agirrezabal I, et al. Selective internal radiation therapy using y-90 resin microspheres for metastatic colorectal cancer: an updated systematic review and network meta-analysis[J]. Adv Ther, 2024, 41(4): 1606-1620. DOI: 10.1007/s12325-024-02800-5.
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (22) PDF downloads (11) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return